Latham & Watkins Named Capital Markets Law Firm of the Year
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Nathan Beaton advises healthcare and life sciences companies and their investors and lenders on matters involving the Food and Drug Administration (FDA) and other regulatory authorities with jurisdiction over healthcare and biotechnology.
Mr. Beaton’s practice spans regulatory, transactional, litigation, and legislative matters involving FDA-regulated industries. He helps clients, from emerging companies to market leaders, navigate the most complex aspects of FDA regulation and oversight. Mr. Beaton also advises on legislation and rulemaking and has been involved extensively in Administrative Procedure Act (APA) litigation, challenging and defending FDA actions and regulatory programs.
Mr. Beaton leverages his regulatory expertise and industry knowledge to advise clients on transactions in the healthcare and life sciences sectors. He helps clients to evaluate regulatory risks and opportunities in the context of a range of transactions, including:
A recognized thought leader, Mr. Beaton frequently speaks and writes on healthcare and life sciences topics. He is a member of the Food and Drug Law Journal’s editorial advisory board.
He also maintains an active pro bono practice and previously served on the firm’s Pro Bono Committee.
Mr. Beaton’s recent publications and speaking engagements include:
Mr. Beaton’s representative healthcare and life sciences clients include:
He regularly counsels at all stages of the product life cycle, including:
Mr. Beaton’s recent transactional experience includes representing:
His recent litigation experience includes representing:
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Chambers USA recognized the firm’s Mergers & Acquisitions Practice for “world class expertise when it comes to the most challenging transactions.”